Sedia Biosciences (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.50 M
- Company Age 2 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
About Sedia Biosciences (India)
Sedia Biosciences (India) Private Limited (SBIPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 23 November 2022 (Two years and two months 19 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sujata Rajindar, Roger Gale, and Ronald Mink serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33111MH2022FTC394041
-
Company No.
394041
-
Company Classification
Private Limited Foreign Company Incorporated In India
-
Incorporation Date
23 Nov 2022
-
Date of AGM
23 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Sedia Biosciences (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujata Rajindar
|
Director | 23-Nov-2022 | Current |
Roger Gale
|
Whole-Time Director | 23-Nov-2022 | Current |
| Ronald Mink | Whole-Time Director | 23-Nov-2022 | Current |
Financial Performance of Sedia Biosciences (India).
Sedia Biosciences (India) Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sedia Biosciences (India)?
Unlock access to Sedia Biosciences (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Inditalia Refcon LtdSujata Rajindar is a mutual person
-
Sumit Biosciences Private LimitedSujata Rajindar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sedia Biosciences (India)?
Unlock and access historical data on people associated with Sedia Biosciences (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sedia Biosciences (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sedia Biosciences (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.